CytomX Therapeutics (NASDAQ:CTMX) Rating Increased to Buy at BidaskClub

CytomX Therapeutics (NASDAQ:CTMX) was upgraded by research analysts at BidaskClub from a “hold” rating to a “buy” rating in a report issued on Friday, BidAskClub reports.

A number of other research analysts have also recently commented on CTMX. Mizuho initiated coverage on shares of CytomX Therapeutics in a report on Wednesday, June 12th. They issued a “buy” rating and a $16.00 target price for the company. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $23.00 price objective (up previously from $21.00) on shares of CytomX Therapeutics in a research note on Monday, June 3rd. Nomura lowered their price objective on CytomX Therapeutics to $22.00 in a research note on Monday, May 13th. HC Wainwright reaffirmed a “buy” rating and issued a $1.75 price objective on shares of Orion Energy Systems in a research note on Wednesday, April 3rd. Finally, ValuEngine downgraded Zosano Pharma from a “buy” rating to a “hold” rating in a research note on Wednesday, May 1st. Two analysts have rated the stock with a sell rating, one has issued a hold rating and ten have given a buy rating to the company. The company currently has an average rating of “Buy” and an average price target of $20.72.

CTMX stock opened at $11.82 on Friday. The company has a market capitalization of $535.56 million, a PE ratio of -5.82 and a beta of 0.64. The company has a debt-to-equity ratio of 0.22, a current ratio of 4.21 and a quick ratio of 4.21. CytomX Therapeutics has a 12 month low of $8.94 and a 12 month high of $27.20. The business has a 50-day moving average of $10.75.



CytomX Therapeutics (NASDAQ:CTMX) last posted its earnings results on Thursday, May 9th. The biotechnology company reported ($0.31) EPS for the quarter, topping analysts’ consensus estimates of ($0.53) by $0.22. The firm had revenue of $29.49 million during the quarter, compared to analysts’ expectations of $13.59 million. CytomX Therapeutics had a negative net margin of 111.27% and a negative return on equity of 73.62%. Sell-side analysts forecast that CytomX Therapeutics will post -2.13 EPS for the current fiscal year.

Several institutional investors have recently added to or reduced their stakes in CTMX. BNP Paribas Arbitrage SA increased its stake in shares of CytomX Therapeutics by 84,072.7% in the first quarter. BNP Paribas Arbitrage SA now owns 9,259 shares of the biotechnology company’s stock valued at $100,000 after buying an additional 9,248 shares during the period. Legal & General Group Plc increased its position in CytomX Therapeutics by 18.6% during the 4th quarter. Legal & General Group Plc now owns 8,342 shares of the biotechnology company’s stock valued at $126,000 after purchasing an additional 1,306 shares during the period. Deltec Asset Management LLC acquired a new stake in CytomX Therapeutics during the 1st quarter valued at approximately $129,000. Metropolitan Life Insurance Co. NY increased its position in CytomX Therapeutics by 376.5% during the 4th quarter. Metropolitan Life Insurance Co. NY now owns 13,479 shares of the biotechnology company’s stock valued at $204,000 after purchasing an additional 10,650 shares during the period. Finally, First Trust Advisors LP acquired a new stake in CytomX Therapeutics during the 1st quarter valued at approximately $263,000. 81.83% of the stock is owned by institutional investors.

CytomX Therapeutics Company Profile

CytomX Therapeutics, Inc operates as an oncology-focused biopharmaceutical company in the United States. The company develops a novel class of investigational antibody therapeutics based on its Probody technology platform for the treatment of cancer. Its product candidates in clinical stage include CX-072, a Probody therapeutic targeting programmed cell death ligand 1 immuno-oncology target; CX-2009, a Probody drug conjugate (PDC) against CD166 novel drug target; BMS-986249, a CTLA-4 Probody therapeutic drug; CX-2029, a PDC targeting CD71; and CX-188, a Probody therapeutic targeting PD-1 anti-cancer target.

Recommended Story: Why is total return important?

Analyst Recommendations for CytomX Therapeutics (NASDAQ:CTMX)

Receive News & Ratings for CytomX Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytomX Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.